Price movement over the last 24 hours
Adaptive Biotechnologies Corp vs iShares Semiconductor ETF — how do they compare? Adaptive Biotechnologies Corp trades at $19.87 (market cap $3.33B), while iShares Semiconductor ETF trades at $560.72. Which is the better fit depends on your goals.
| ADPT | SOXX | |
|---|---|---|
Market Cap | $3.33B | — |
Sector | Health | Sector/Thematic |
52-Week High | $22.37 | $655.01 |
52-Week Low | $10.24 | $236.93 |
Enterprise Value | $3.19B | — |
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
SOXX, the iShares Semiconductor ETF, trades at $581.51, up 2.68% in the last 24 hours, with a neutral technical signal but bullish moving averages. The ETF has surged 93.3% year-to-date, driven by AI chip demand, yet faces recent volatility as hedge funds reduced exposure. Key support sits at $575, with resistance at $593. Financial ratios are not applicable for this ETF structure, which holds 30 U.S. semiconductor stocks.
Outlook remains cautiously optimistic given AI-driven growth, but risks include sector rotation, valuation concerns after sharp gains, and macroeconomic pressures. JPMorgan advises buying the dip, while Morgan Stanley notes potential pivot to hyperscalers. Investors should weigh strong thematic tailwinds against near-term volatility and high beta exposure.
Trailing returns across standard periods
Latest headlines on both assets
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →SOXX provides investors with exposure to U.S. companies that design, manufacture, and distribute semiconductors. It tracks the ICE Semiconductor Index, offering a targeted investment in the technology sector's foundational components, including firms that produce chips, related equipment, and services. SOXX is a key vehicle for investors seeking to capitalize on trends in artificial intelligence, 5G, and other technologies that rely heavily on advanced semiconductor technology.
Read more on SOXX →